stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Return on assets
Ascendis Pharma A/S's return on assets over the twelve months to 30 June 2026 was 44.3%, up 63.1 percentage points from fiscal 2025 (−18.8%). Over the past ten years it has ranged from −62.4% (fiscal 2017) to −18.8% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −18.8% | 18.95 |
| FY2024 | −37.7% | 13.33 |
| FY2023 | −51.0% | (0.50) |
| FY2022 | −50.5% | (12.77) |
| FY2021 | −37.8% | 13.22 |
| FY2020 | −51.0% | (7.95) |
| FY2019 | −43.0% | 6.91 |
| FY2018 | −50.0% | 12.46 |
| FY2017 | −62.4% | (19.90) |
| FY2016 | −42.5% | (9.92) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S | 44.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| HALO Halozyme Therapeutics, Inc. compare | 17.1% |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.76% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement